COMPLETED

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.

Official Title

A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Quick Facts

Study Start:2025-03-07
Study Completion:2025-09-19
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06854952

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Female or male aged 18 to 75 years
  2. 2. Body mass index (BMI) of:
  3. 1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2
  4. 2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
  5. 3. HbA1c \< 6.5%
  6. 4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)
  1. 1. Have diabetes mellitus
  2. 2. Have obesity induced by medication or other diagnosed endocrinologic disorders
  3. 3. Have had or are planning surgical treatment or device-based therapy for obesity
  4. 4. Lifetime history of suicide attempt

Contacts and Locations

Study Locations (Sites)

FALCON Research Site
Birmingham, Alabama, 35294
United States
FALCON Research Site
Homewood, Alabama, 35209
United States
FALCON Research Site
Tucson, Arizona, 85712
United States
FALCON Research Site
Spring Valley, California, 91978
United States
FALCON Research Site
Port Orange, Florida, 32127
United States
FALCON Research Site
Louisville, Kentucky, 40213
United States
FALCON Research Site
Marrero, Louisiana, 70072
United States
FALCON Research Site
Boston, Massachusetts, 02114
United States
FALCON Research Site
Rochester, Minnesota, 55905
United States
FALCON Research Site
City of Saint Peters, Missouri, 63303
United States
FALCON Research Site
Beachwood, Ohio, 44122
United States
FALCON Research Site
Medford, Oregon, 97504
United States
FALCON Research Site
Dallas, Texas, 75230
United States
FALCON Research Site
Houston, Texas, 77079
United States
FALCON Research Site
San Antonio, Texas, 78229
United States
FALCON Research Site
St. George, Utah, 84790
United States
FALCON Research Site
Arlington, Virginia, 22206
United States

Collaborators and Investigators

Sponsor: Terns, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-07
Study Completion Date2025-09-19

Study Record Updates

Study Start Date2025-03-07
Study Completion Date2025-09-19

Terms related to this study

Keywords Provided by Researchers

  • overweight
  • obesity
  • obese
  • glucagon-like peptide-1 receptor agonist
  • GLP-1 receptor agonist
  • GLP-1

Additional Relevant MeSH Terms

  • Overweight or Obesity